The triple-G drug produced roughly double the weight loss of Novo Nordisk's Ozempic, though with higher rates of side effects and treatment discontinuations.

The Moderna-Merck cancer vaccine results, presented at ESMO, were hailed as a major step for personalized cancer therapy, though overall survival benefit remain

Positive data for the antibody acquired in Genmab's $8 billion Merus deal sent shares up sharply, adding more than $7 billion in market value.

Starting in 2027, pharmacy benefit managers must share fee and compensation details with self-funded employer clients; employers backed the rule while PBMs call

The framework, developed with CMS, offers an approval pathway for individualized gene editing therapies benefiting patient subsets with the same disease.

The approval marks a new treatment approach for chronic hepatitis B, a virus affecting hundreds of millions worldwide.

The setback hit one of the top-performing biotech stocks, raising questions about the broader applicability of its tumor-infiltrating lymphocyte therapy.

RFK Jr.'s policy grants enforcement discretion for peptides that won a contested FDA advisory recommendation, over objections from FDA career scientists.

The deal adds another cancer immunotherapy prospect to Astellas' pipeline as large pharma continues to buy into early-stage oncology assets.

The funding supports late-stage development of the company's bispecific antibody program in rare blood cancers.

The deal expands Ferring's fertility portfolio through Gameto's stem-cell-based reproductive medicine programs.

The approval ends a decades-long drought for patients with the condition and marks a milestone for rare disease drug development.

The ruling found federal regulators exceeded their authority in narrowing medical exceptions to Medicaid work requirements.

The approval provides a new option for patients with advanced pancreatic cancer who have already received prior therapy.

Early trial results showed near-universal immune response, though clinical benefit has yet to be established.

The move gives a regulatory boost to the peptide craze embraced by RFK Jr. and the MAHA movement, despite limited evidence for many compounds.

The FDA is set to decide on the drug by Nov 30, with reviewers focused on infection risk in the lead-up to the decision.

Etiome, Cellarity and Empress Therapeutics are being combined into one company claiming better prediction of how new medicines will perform in humans.